Published online Dec 15, 2023. doi: 10.4239/wjd.v14.i12.1849
Peer-review started: September 15, 2023
First decision: September 20, 2023
Revised: September 29, 2023
Accepted: October 23, 2023
Article in press: October 23, 2023
Published online: December 15, 2023
Processing time: 90 Days and 6.2 Hours
People with diabetes mellitus (DM) suffer from multiple chronic complications due to sustained hyperglycemia, especially diabetic cardiomyopathy (DCM). Oxidative stress and inflammatory cells play crucial roles in the occurrence and progression of myocardial remodeling. Macrophages polarize to two distinct phenotypes: M1 and M2, and such plasticity in phenotypes provide macrophages various biological functions.
To investigate the effect of atorvastatin on cardiac function of DCM in db/db mice and its underlying mechanisms.
DCM mouse models were established and randomly divided into DM, atorvastatin, and metformin groups. C57BL/6 mice were used as the control. Cardiac function was evaluated by echocardiography. Hematoxylin and eosin and Masson staining was used to examine the morphology and collagen fibers in myocardial tissues. The expression of transforming growth factor-β1 (TGF-β1), tumor necrosis factor-α (TNF-α), interleukin-1 β (IL-1β),M1 macrophages (iNOS+), and M2 macrophages (CD206+) were demonstrated by immunohistochemistry and immunofluorescence staining. The levels of TGF-β1, IL-1β, and TNF-α were detected by ELISA and real-time quantitative polymerase chain reaction. Malondialdehyde (MDA) concentrations and superoxide dismutase (SOD) ac-tivities were also measured.
Treatment with atorvastatin alleviated cardiac dysfunction and decreased db/db mice. The broken myocardial fibers and deposition of collagen in the myocardial interstitium were relieved especially by atorvastatin treatment. Atorvastatin also reduced the levels of serum lactate dehydrogenase, creatine kinase isoenzyme, and troponin; lowered the levels of TGF-β1, TNF-α and IL-1β in serum and myocardium; decreased the concentration of MDA and increased SOD activity in myocardium of db/db mice; inhibited M1 macrophages; and promoted M2 macrophages.
Administration of atorvastatin attenuates myocardial fibrosis in db/db mice, which may be associated with the antioxidative stress and anti-inflammatory effects of atorvastatin on diabetic myocardium through modulating macrophage polarization.
Core Tip: The occurrence and development of diabetic cardiomyopathy are accompanied by a few pathological mechanisms. The present study showed that atorvastatin had antioxidant properties on diabetic hearts. Cardiac tissues include many resident macrophages. In high glucose conditions, macrophages can upregulate glucose uptake and utilization and enhance the production of inflammatory cytokines. Dysregulation of macrophages between M1 and M2 phenotypes causes excessive inflammation and cardiac injury. Our study suggests that administration of atorvastatin attenuates myocardial fibrosis in db/db mice, which may be associated with the antioxidative stress and anti-inflammatory effects of atorvastatin on diabetic myocardium through modulating macrophage polarization.
- Citation: Song XM, Zhao MN, Li GZ, Li N, Wang T, Zhou H. Atorvastatin ameliorated myocardial fibrosis in db/db mice by inhibiting oxidative stress and modulating macrophage polarization. World J Diabetes 2023; 14(12): 1849-1861
- URL: https://www.wjgnet.com/1948-9358/full/v14/i12/1849.htm
- DOI: https://dx.doi.org/10.4239/wjd.v14.i12.1849
The prevalence of diabetes mellitus (DM) is rising around the world, and is becoming a significant concern for global health. People with DM suffer from multiple chronic complications due to sustained hyperglycemia, especially diabetic cardiomyopathy (DCM). DCM is defined as myocardial structural abnormality and cardiac dysfunction, characterized by early diastolic dysfunction and further obstacle of systolic function, which ultimately leads to refractory heart failure (HF), independent of hypertension, coronary artery disease, or heart valvular disease[1]. Autophagy dysregulation, abnormal mitochondrial energetics, oxidative stress, inflammation, impaired calcium homeostasis, and activation of the renin–angiotensin–aldosterone system are all involved in the pathogenesis of DCM[2]. The pathological changes of DCM mainly contain cardiomyocyte hypertrophy, apoptosis, and myocardial fibrosis. Cardiac fibrosis is a major contributor to cardiac dysfunction, which ultimately increases the incidence of hospitalization due to HF and the mortality in patients with DM. However, there is currently no specific treatment for DCM at the early stage.
DM is a mild, chronic inflammatory condition characterized by the excessive secretion of proinflammatory cytokines, which can lead to cardiovascular complications[3]. Oxidative stress and inflammatory cells play crucial roles in the occurrence and progression of myocardium remodeling. High-glucose-induced oxidative stress can induce cardiac fibroblasts switching to a profibrotic phenotype that leads to cardiac fibrosis[4-6]. Cardiac fibrosis is mediated by a number of inflammatory cytokines, such as transforming growth factor-β1 (TGF-β1), tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β). As a profibrotic regulator, TGF-β1 regulates fibroblast to myofibroblast transformation[7]. In our previous study, we observed an increase in Smad2/3 phosphorylation in the hearts of diabetic rats, coupled with elevated mRNA and protein levels of TGF-β1. JNK and Smad2/3 may serve as downstream signaling molecules within the RhoA/ROCK pathway and play a role in the development of myocardial fibrosis in type 2 DM (T2DM) rats[8]. Che et al[9] also discovered that inhibiting the TGF-β1/Smads signaling pathway significantly ameliorated cardiac dysfunction and reduced collagen production in DM mice. Inhibition of TNF-α has been shown to reduce cardiac fibrosis and improve cardiac function, contributing to the amelioration of DCM[10,11]. Hsuan et al[2] demonstrated that inhibiting the p38 mitogen-activated protein kinase stress pathway decreased inflammatory cytokines such as TNF-α and IL-1β in diabetic hearts, thus improving left ventricular dysfunction in DCM. Similarly, IL-1β plays a significant role in the path
Metformin is a first-line glycemic control drug that can decrease glycogen output and increase peripheral tissue uptake of glucose, thus ameliorating insulin resistance[19]. It is reported that metformin protects against DCM through attenuating cardiac apoptosis and fibrosis[20,21]. Therefore, metformin has been commonly used as the positive drug control for T2DM[22]. Statins are lipid-lowering drugs, possessing anti-inflammatory and antioxidative effects. This study aimed to investigate the effect of atorvastatin on cardiac function of DCM in db/db mice and its underlying mechanisms.
Six-week-old male db/db mice and C57BL/6 mice were purchased from the HFK Bio-Technology Co. Ltd. (Beijing, China) (Approval No. SCXK 2020-0004). All procedures were approved by the Animal Experimental Ethics Committee of the Second Hospital of Hebei Medical University and the Animal Health Care Guidelines to minimize animal suffering. All mice were housed in standard cages (5 mice/cage) and were fed in a room with moderate temperature (22 ± 2°C), appropriate humidity (55% ± 5%), a 12/12 h light/dark cycle, with chow diet and water ad libitum. At 8 wk of age, blood glucose levels were measured from the tail vein using a portable glucometer (Accu-Chek Active; Roche Diagnostics, Mannheim, Germany). The db/db mice were considered to have T2DM if their blood glucose level was ≥ 16.7 mmol/L[23]. The diabetic mice were randomly divided into three groups: DM: db/db mice received daily oral gavage of sterilized water; atorvastatin group (DM + ATO): db/db mice received daily oral gavage of 10 mg/kg/d atorvastatin; metformin group (DM + MET): db/db mice received daily oral gavage of 200 mg/kg metformin. The C57BL/6 mice were used as the control group (CON). Each group contained five mice. Metformin hydrochloride tablets were purchased from Sino-American Shanghai Squibb Pharmaceutical Co. Ltd. (Shanghai, China), and atorvastatin calcium was purchased from Pfizer (New York, USA). Both drugs were dissolved in sterilized water and administrated through gastric gavage once per day for 16 wk.
At 24 wk of age, following a 12-h fast, blood samples were collected from the ophthalmic vein of mice under anesthesia. Systolic arterial blood pressure (SABP) was measured by tail-cuff micro-photoelectric plethysmography. Fasting blood was collected from the mice. Fasting blood glucose (FBG), glycosylated hemoglobin (HbA1c), total cholesterol (TC), triglyceride (TG), lactate dehydrogenase (LDH), creatine kinase isoenzyme (CK-MB), troponin (cTnI), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) were measured using the automatic biochemical instrument of the Second Hospital of Hebei Medical University. Cardiac function was evaluated by echocardiography. The mice were killed by cervical dislocation after 4% chloral hydrate anesthesia (0.20 mL/20 g; i.p.), and the cardiac muscle tissues were collected during chest surgery for analysis.
Mice were anesthetized using 1.5% maintenance of isoflurane, and their heart rates were maintained between 400 and 500 beats/min. VEVO 3100 imaging system (Visual Sonics Inc., Toronto, ON, Canada) was used to perform echocardiography under M-mode. The left ventricle, the left ventricular ejection fraction (LVEF), the left ventricular fractional shortening (LVFS), the left ventricular internal dimension in systole (LVIDs), and the left ventricular end-diastolic diameter (LVIDd) were recorded.
The heart tissues were fixed in 4% paraformaldehyde and then embedded in paraffin. Tissue sections from the paraffin-embedded samples were stained following hematoxylin and eosin (HE) and Masson’s trichrome staining. The myocardial staining was visualized and recorded under an optical microscope. HE and Masson staining was used to examine the changes of morphology and collagen fibers in myocardial tissues. Three sections and fields were investigated in histological evaluations in each group.
Specimens of myocardium were fixed in 4% paraformaldehyde and embedded in paraffin. The paraffin blocks were cut into 5-μm thick sections and heated for 10 min in 0.01 mol/L sodium citrate buffer with a microwave oven for antigen retrieval. Subsequently, 3% hydrogen peroxide was added to quench endogenous peroxidase activity. The sections were then blocked with 10% nonimmune goat serum to reduce nonspecific binding and incubated with 1:200 diluted anti-TGF-β1, 1:500 diluted anti-TNF-α, and 1:500 diluted anti-IL-1β antibodies (Abways, China) overnight at 4°C. After washing in phosphate-buffered saline (PBS), horseradish peroxidase (HRP)-conjugated secondary antibody was added and incubated with diaminobenzidine tetrahydrochloride. The sections were mounted on slides, stained with hematoxylin, and dehydrated in graded alcohol.
The paraffin blocks were cut into 5-μm thick sections, blocked with 10% nonimmune goat serum to reduce nonspecific binding, incubated with 1:100 diluted CD206 (Santa Cruz Biotechnology, Dallas, TX, USA) and 1:100 diluted inducible nitric oxide synthase (iNOS) (eBioscience, San Diego, CA, USA) antibodies overnight at 4C. After washing in PBS, HRP-conjugated secondary antibody was added and incubated for an additional 30 min at 37C. 4,6-diamidino-2-phenylindole (DAPI) was used to detect the nucleated cells. Images were visualized under a fluorescence microscope (Olympus, Tokyo, Japan). Three sections and fields were investigated for histological evaluations in each group.
The levels of TGF-β1, IL-1β, and TNF-α in the serum samples were detected using ELISA kits (Multi Sciences, Hangzhou, China). Fasting insulin (FINS) was measured using another ELISA kit (Senberga, Nanjing, China).
Cardiac muscle tissues were homogenized, and the supernatants were harvested. Malondialdehyde (MDA) concentrations and superoxide dismutase (SOD) activities in myocardium were examined using commercial assay kits (Nanjing Jiancheng Biological Engineering Institute, Nanjing, China).
Total RNA was extracted using RNA-easyTM Isolation Reagent (Vazyme, Nanjing, China), and real-time quantitative polymerase chain reaction (RT-qPCR) was performed using GoTaq qPCR Master Mix (Promega, Madison, WI, USA). The primers were provided by Sangon Biotechnology (Shanghai, China). The primers are shown in Table 1 The relative expression of the target mRNA was calculated by the 2ΔΔCT method.
| Gene | Primer | Tm (°C) | Product length | Accession |
| TGF-β1 | Forward: 5’-CTCCCGTGGCTTCTAGTGC-3’ | 60.15 | 133 | NM_011577.2 |
| Reverse: 5’-GCCTTAGTTTGGACAGGATCTG-3’ | 58.73 | |||
| TNF-α | Forward: 5’-CCCTCACACTCAGATCATCTTCT-3’ | 59.29 | 61 | NM_013693.3 |
| Reverse: 5’-GCTACGACGTGGGCTACAG-3’ | 60.23 | |||
| IL-1β | Forward: 5’-GCAACTGTTCCTGAACTCAACT-3’ | 59.05 | 89 | NM_008361.4 |
| Reverse: 5’-ATCTTTTGGGGTCCGTCAACT-3’ | 59.58 | |||
| 18S rRNA | Forward: 5’-AGGGGAGAGCGGGTAAGAGA-3’ | 61.58 | 241 | AH002077.2 |
| Reverse: 5’-GGACAGGACTAGGCGGAACA-3’ | 61.26 |
Data were analyzed by GraphPad Prism.9.0 software (GraphPad, La Jolla, CA, USA) and expressed as mean ± SD. The differences among multiple groups were analyzed using one-way analysis of variance, followed by the Tukey test if F was significant. P < 0.05 was considered a statistical difference.
FBG, FINS, HbA1c, TG and TC of the db/db mice were higher than those of the control mice (Table 2). Atorvastatin treatment of db/db mice markedly decreased their TC, but had no effects on FBG, FINS, HbA1c or TG. The db/db mice treated with metformin exhibited lower levels of FBG, FINS and HbA1c than those in the atorvastatin treatment group. There were no significant differences in SABP among the four groups.
| Parameters | CON, n = 5 | DM, n = 5 | DM + ATO, n = 5 | DM + MET, n = 5 |
| FBG (mmol/L) | 5.12 ± 0.11 | 31.81 ± 3.27b | 33.19 ± 3.13b | 10.16 ± 2.92a,c,d |
| FINS (mU/L) | 62.82 ± 4.98 | 281.24 ± 15.47b | 290.10 ± 18.39b | 104.13 ± 8.99a,c,d |
| HbA1c (%) | 5.51 ± 0.60 | 9.57 ± 0.58b | 9.42 ± 0.47b | 7.15 ± 0.84a,c,d |
| ALT (IU/L) | 58.95 ± 9.88 | 67.75 ± 11.30 | 69.03 ± 14.29 | 73.49 ± 15.68 |
| AST (IU/L) | 131.3 ± 27.12 | 157.3 ± 30.36 | 139.7 ± 28.49 | 143.9 ± 32.19 |
| TG (mmol/L) | 1.10 ± 0.17 | 2.48 ± 0.46b | 2.29 ± 0.33b | 2.17 ± 0.25b |
| TC (mmol/L) | 2.22 ± 0.25 | 3.77 ± 0.39a | 2.15 ± 0.38c | 3.29 ± 0.32a,d |
| SABP (mmHg) | 123.9 ± 3.09 | 133.9 ± 5.96 | 129.6 ± 4.88 | 136.4 ± 5.71 |
| HW/BW (× 10-3) | 4.37 ± 0.55 | 6.25 ± 0.38a | 4.89 ± 0.10c | 5.01 ± 0.46c |
db/db mice had significant increased LVIDd and LVIDs, accompanied by a significant reduction in LVFS and LVEF, while the atorvastatin treatment significantly decreased their LVIDd level and augmented their LVFS and LVFF levels (Figure 1). Metformin treatment of db/db mice decreased LVIDd and LVIDs, but had no effects on LVFS and LVEF. The heart weight/body weight (HW/BW) of the db/db mice was significantly higher than that of the control mice, and treatment with atorvastatin or metformin significantly lowered HW/BW (Table 2). To evaluate the histological changes in the myocardium, HE and Masson staining was performed. db/db mice displayed disorganized and broken myocardial fibers and irregular nucleus and deposition of collagen in the myocardial interstitium, which were relieved by either atorvastatin or metformin treatment, especially atorvastatin (Figure 2). Compared with the control mice, the db/db mice had elevated serum levels of CK-MB, LDH and cTnI, indicating myocardial injury, while atorvastatin or metformin treatment decreased the serum levels of LDH, CK-MB and cTnI in db/db mice (Figure 3).
Compared with the control mice, the serum levels and mRNA expression of TGF-β1, TNF-α and IL-1β in the myocardium were markedly elevated, while atorvastatin treatment markedly lowered these indicators in the serum and myocardium of db/db mice. Metformin treatment of db/db mice had no effects on the mRNA expression of IL-1β in the myocardium. The results of immunohistochemical staining of TGF-β1, TNF-α and IL-1β in the myocardium were consistent with those in the serum (Figures 3 and 4). Compared with the control mice, MDA concentration in cardiac muscle tissues of db/db mice was significantly increased, while SOD activity was significantly decreased. Compared with the db/db mice, atorvastatin or metformin treatment reduced MDA concentration and enhanced SOD activity in the myocardium (Figure 5).
Immunofluorescence staining of macrophages showed increased M1 proinflammatory macrophages (INOS+) and decreased M2 anti-inflammatory macrophages (CD206+) in the myocardium of db/db mice. Atorvastatin treatment reduced the expression of M1 macrophages and promoted expression of M2 macrophages. However, metformin treatment increased expression of M2 macrophages and had no effects on the expression of M1 macrophages in the myocardium of db/db mice (Figure 5).
The incidence of HF has increased in patients with DM, which is closely related to DCM. The development of DCM initiates from subtle myocardial changes to myocardial fibrosis and diastolic dysfunction and eventually to stubborn HF. Cardiac fibrosis is one of the primary characteristics of DCM that contributes to the development of adverse cardiac remodeling and myocardial stiffness[24]. Hyperglycemia, hyperlipidemia, hyperinsulinemia, and impaired insulin signaling are the main initiators of DCM[25]. db/db mice are often used as a typical animal model of T2DM. In our study, the db/db mice exhibited hyperglycemia, hyperlipidemia and hyperinsulinemia, indicating a feature of T2DM. At 24 wk old, the db/db mice showed a significant increase in LVIDd and LVIDs and a significant reduction in LVFS and LVEF, as shown by echocardiography, suggesting cardiac diastolic and systolic dysfunction. The HW/BW of the db/db mice was significantly higher than that of the control mice; in combination with the results from HE and Masson staining, these findings manifested as myocardial pathological hypertrophy and fibrosis in the db/db mice. The elevated serum levels of CK-MB, LDH and cTnI also suggested myocardial injury of the db/db mice. Therefore, the db/db mice had developed DCM.
Metformin is a widely used glucose-lowering drug and has been confirmed to exert cardioprotective effects by improving the morphology and structure of the heart in db/db mice[20,26]. Metformin ameliorates DCM by inhibiting myocardial inflammation and oxidative stress, mainly through the activation of mitogen-activated protein kinase and promotion of autophagic flux[20,27,28]. At present, there is ample clinical evidence supporting the notion that metformin can reduce the risk of cardiovascular rehospitalization in diabetic patients with HF, and decrease the high risk of exacerbating DCM in prediabetic patients[29,30]. A recent meta-regression analysis has demonstrated that metformin is associated with reduced mortality in patients with HF with preserved ejection fraction, resulting in an 18% decrease in mortality for all HF patients[31]. Although metformin can be used safely in T2DM patients complicated with HF, it should be noted that currently metformin is drugs and have become the first-line choice for patients suffering from cardiovascular diseases. In addition to lowering blood fat, statins possess multiple pleiotropic effects. Previous studies have shown that statins can prevent DCM by alleviating myocardial fibrosis through antioxidative stress and anti-inflammatory pathways[33,34]. Greig et al[35] showed that atorvastatin reduced the levels of oxidative stress and inflammation and restored endothelial dysfunction in patients with HF. Taking a daily dose of 40 mg of simvastatin reduced the risk of major adverse cardiovascular events by ~25% in diabetic patients[36]. Similarly, our study also demonstrated that atorvastatin inhibited myocardial injury and fibrosis, which contribute to DCM attenuation.
The occurrence and development of DCM is accompanied by oxidative stress and chronic inflammation[37,38]. Oxidative stress can prompt the transformation of fibroblasts to myofibroblasts, leading to cardiac fibrosis[39,40]. The present study displayed that atorvastatin had antioxidant properties in diabetic hearts. Cardiac tissues include a plenty of resident macrophages. Under high glucose conditions, macrophages can upregulate glucose uptake and utilization and enhance the production of inflammatory cytokines, such as TGF-β1 and TNF-α, which act on macrophages and promote the activation of inflammatory phenotype M1[41]. Dysregulation of macrophages between M1 and M2 phenotypes causes excessive inflammation and cardiac injury[42]. Macrophages can also promote cardiac fibrosis through either directly producing extracellular matrix proteins or stimulating fibroblasts to secret TGF-β1[25]. Widiapradja et al[6] showed that only M2 macrophages were found in normal mouse hearts without inflammation, but there was a predominant increase in M1 macrophages in diabetic hearts, leading to a significant increased M1/M2 ratio. Liu et al[43] also had similar findings for the hearts of T2DM mice. We observed the distribution of M1 (CD86+) and M2 (CD206+) macrophages in the hearts of the db/db mice and found that M1 macrophages were increased in diabetic hearts. It has been reported that the imbalance of M1/M2 ratio can accelerate the development of DCM[17], and the regulation of macrophage polarization can improve the cardiac function of DCM[18]. These results demonstrate that inflammatory polarization of macrophages plays an important role in the development of DCM. Our study showed that atorvastatin reduced the expression of M1 macrophages and increased M2 macrophages in the hearts of db/db mice, and concurrently decreased the levels of TGF-β1, TNF-α and IL-1β in both the myocardium and the serum. These findings are consistent with those from the study by Jia et al[28].
Our study suggests that administration of atorvastatin attenuates myocardial fibrosis in db/db mice, which may be associated with the antioxidative stress and anti-inflammatory effects of atorvastatin on diabetic myocardium through modulating macrophage polarization. The investigation of cardiac macrophage polarization will facilitate DCM treatment by targeting macrophage metabolism in the hearts (Figure 6).
Statins were initially used to lower blood lipids; however, in addition to their lipid-lowering effects, statins are involved in the regulation of the inflammatory response and play an important role in cardiovascular protection. Macrophage polarization is involved in a variety of pathological processes. Macrophage polarization is likewise involved in the development of diabetic cardiomyopathy (DCM).
DCM is one of the serious complications of diabetes mellitus, and we wanted to explore whether atorvastatin could mitigate the effects on DCM by affecting macrophage polarization to reduce oxidative stress, inflammation, and cardiac fibrosis.
We used db/db mice as a type 2 diabetes model and randomly divided into three groups: The db/db mice received daily oral gavage of sterilized water group, atorvastatin group and metformin group. C56BL/6 mice were used as the control group.
Cardiac function was evaluated by echocardiography. Histological evaluations are hematoxylin and eosin staining, Masson staining, immunohistochemistry, and immunofluorescence. ELISA and real-time quantitative polymerase chain reaction were also used.
Treatment with atorvastatin improved cardiac dysfunction in db/db mice. Atorvastatin reduced the levels of serum myocardial injury markers; lowered the levels of Inflammatory cytokines in serum and myocardium; decreased indicators of oxidative stress in myocardium of db/db mice; inhibited M1 macrophages and promoted M2 macrophages.
Administration of atorvastatin attenuates myocardial fibrosis in db/db mice, which may be associated through modulating macrophage polarization.
Our study further confirms the protective role of statins in cardiovascular disease and provides a new therapeutic target for DCM.
Provenance and peer review: Unsolicited article; Externally peer reviewed.
Peer-review model: Single blind
Specialty type: Endocrinology and metabolism
Country/Territory of origin: China
Peer-review report’s scientific quality classification
Grade A (Excellent): 0
Grade B (Very good): B, B
Grade C (Good): C
Grade D (Fair): 0
Grade E (Poor): 0
P-Reviewer: Mostafavinia A, Iran; Pappachan JM, United Kingdom S-Editor: Wang JJ L-Editor: Kerr C P-Editor: Cai YX
| 1. | Jia G, Hill MA, Sowers JR. Diabetic Cardiomyopathy: An Update of Mechanisms Contributing to This Clinical Entity. Circ Res. 2018;122:624-638. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 689] [Cited by in F6Publishing: 1017] [Article Influence: 203.4] [Reference Citation Analysis (0)] |
| 2. | Hsuan CF, Teng SIF, Hsu CN, Liao D, Chang AJ, Lee HL, Hee SW, Chang YC, Chuang LM. Emerging Therapy for Diabetic Cardiomyopathy: From Molecular Mechanism to Clinical Practice. Biomedicines. 2023;11. [PubMed] [DOI] [Cited in This Article: ] [Reference Citation Analysis (0)] |
| 3. | Peiró C, Lorenzo Ó, Carraro R, Sánchez-Ferrer CF. IL-1β Inhibition in Cardiovascular Complications Associated to Diabetes Mellitus. Front Pharmacol. 2017;8:363. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 68] [Cited by in F6Publishing: 86] [Article Influence: 12.3] [Reference Citation Analysis (0)] |
| 4. | De Geest B, Mishra M. Role of Oxidative Stress in Heart Failure: Insights from Gene Transfer Studies. Biomedicines. 2021;9. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 6] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis (0)] |
| 5. | Russo I, Frangogiannis NG. Diabetes-associated cardiac fibrosis: Cellular effectors, molecular mechanisms and therapeutic opportunities. J Mol Cell Cardiol. 2016;90:84-93. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 250] [Cited by in F6Publishing: 307] [Article Influence: 34.1] [Reference Citation Analysis (0)] |
| 6. | Widiapradja A, Kasparian AO, McCaffrey SL, Kolb LL, Imig JD, Lacey JL, Melendez GC, Levick SP. Replacement of Lost Substance P Reduces Fibrosis in the Diabetic Heart by Preventing Adverse Fibroblast and Macrophage Phenotype Changes. Cells. 2021;10. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis (0)] |
| 7. | Kuo HF, Hsieh CC, Wang SC, Chang CY, Hung CH, Kuo PL, Liu YR, Li CY, Liu PL. Simvastatin Attenuates Cardiac Fibrosis via Regulation of Cardiomyocyte-Derived Exosome Secretion. J Clin Med. 2019;8. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 21] [Cited by in F6Publishing: 32] [Article Influence: 6.4] [Reference Citation Analysis (0)] |
| 8. | Zhou H, Li YJ, Wang M, Zhang LH, Guo BY, Zhao ZS, Meng FL, Deng YG, Wang RY. Involvement of RhoA/ROCK in myocardial fibrosis in a rat model of type 2 diabetes. Acta Pharmacol Sin. 2011;32:999-1008. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 56] [Cited by in F6Publishing: 60] [Article Influence: 4.6] [Reference Citation Analysis (0)] |
| 9. | Che H, Wang Y, Li H, Li Y, Sahil A, Lv J, Liu Y, Yang Z, Dong R, Xue H, Wang L. Melatonin alleviates cardiac fibrosis via inhibiting lncRNA MALAT1/miR-141-mediated NLRP3 inflammasome and TGF-β1/Smads signaling in diabetic cardiomyopathy. FASEB J. 2020;34:5282-5298. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 54] [Cited by in F6Publishing: 93] [Article Influence: 23.3] [Reference Citation Analysis (0)] |
| 10. | Westermann D, Van Linthout S, Dhayat S, Dhayat N, Schmidt A, Noutsias M, Song XY, Spillmann F, Riad A, Schultheiss HP, Tschöpe C. Tumor necrosis factor-alpha antagonism protects from myocardial inflammation and fibrosis in experimental diabetic cardiomyopathy. Basic Res Cardiol. 2007;102:500-507. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 150] [Cited by in F6Publishing: 157] [Article Influence: 9.2] [Reference Citation Analysis (0)] |
| 11. | Duerrschmid C, Crawford JR, Reineke E, Taffet GE, Trial J, Entman ML, Haudek SB. TNF receptor 1 signaling is critically involved in mediating angiotensin-II-induced cardiac fibrosis. J Mol Cell Cardiol. 2013;57:59-67. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 71] [Cited by in F6Publishing: 79] [Article Influence: 7.2] [Reference Citation Analysis (0)] |
| 12. | Liberale L, Carbone F, Camici GG, Montecucco F. IL-1β and Statin Treatment in Patients with Myocardial Infarction and Diabetic Cardiomyopathy. J Clin Med. 2019;8. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis (0)] |
| 13. | Geissmann F, Manz MG, Jung S, Sieweke MH, Merad M, Ley K. Development of monocytes, macrophages, and dendritic cells. Science. 2010;327:656-661. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 2251] [Cited by in F6Publishing: 2148] [Article Influence: 153.4] [Reference Citation Analysis (0)] |
| 14. | Sun K, Li YY, Jin J. A double-edged sword of immuno-microenvironment in cardiac homeostasis and injury repair. Signal Transduct Target Ther. 2021;6:79. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 92] [Cited by in F6Publishing: 97] [Article Influence: 32.3] [Reference Citation Analysis (0)] |
| 15. | Juin SK, Pushpakumar S, Tyagi SC, Sen U. Glucosidase inhibitor, Nimbidiol ameliorates renal fibrosis and dysfunction in type-1 diabetes. Sci Rep. 2022;12:21707. [PubMed] [DOI] [Cited in This Article: ] [Cited by in F6Publishing: 5] [Reference Citation Analysis (0)] |
| 16. | Yunna C, Mengru H, Lei W, Weidong C. Macrophage M1/M2 polarization. Eur J Pharmacol. 2020;877:173090. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 275] [Cited by in F6Publishing: 885] [Article Influence: 221.3] [Reference Citation Analysis (0)] |
| 17. | Jia C, Chen H, Wei M, Chen X, Zhang Y, Cao L, Yuan P, Wang F, Yang G, Ma J. Gold nanoparticle-based miR155 antagonist macrophage delivery restores the cardiac function in ovariectomized diabetic mouse model. Int J Nanomedicine. 2017;12:4963-4979. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 76] [Cited by in F6Publishing: 65] [Article Influence: 9.3] [Reference Citation Analysis (0)] |
| 18. | Sreedhar R, Arumugam S, Thandavarayan RA, Karuppagounder V, Koga Y, Nakamura T, Harima M, Watanabe K. Role of 14-3-3η protein on cardiac fatty acid metabolism and macrophage polarization after high fat diet induced type 2 diabetes mellitus. Int J Biochem Cell Biol. 2017;88:92-99. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis (0)] |
| 19. | Foretz M, Guigas B, Viollet B. Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus. Nat Rev Endocrinol. 2019;15:569-589. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 274] [Cited by in F6Publishing: 333] [Article Influence: 66.6] [Reference Citation Analysis (0)] |
| 20. | Dawood AF, Alzamil NM, Hewett PW, Momenah MA, Dallak M, Kamar SS, Abdel Kader DH, Yassin H, Haidara MA, Maarouf A, Al-Ani B. Metformin Protects against Diabetic Cardiomyopathy: An Association between Desmin-Sarcomere Injury and the iNOS/mTOR/TIMP-1 Fibrosis Axis. Biomedicines. 2022;10. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis (0)] |
| 21. | Packer M. Autophagy-dependent and -independent modulation of oxidative and organellar stress in the diabetic heart by glucose-lowering drugs. Cardiovasc Diabetol. 2020;19:62. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 40] [Cited by in F6Publishing: 57] [Article Influence: 14.3] [Reference Citation Analysis (0)] |
| 22. | Hou N, Mai Y, Qiu X, Yuan W, Li Y, Luo C, Liu Y, Zhang G, Zhao G, Luo JD. Carvacrol Attenuates Diabetic Cardiomyopathy by Modulating the PI3K/AKT/GLUT4 Pathway in Diabetic Mice. Front Pharmacol. 2019;10:998. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 33] [Cited by in F6Publishing: 47] [Article Influence: 9.4] [Reference Citation Analysis (0)] |
| 23. | Yu H, Wang M, Yu J, Tang H, Xu Q, Cheng N, Luo X, Wang Y, Ge H, Qiang L, Tang W, Gu HF. Evaluation of the efficacy of Abelmoschus manihot (L.) on diabetic nephropathy by analyzing biomarkers in the glomeruli and proximal and distal convoluted tubules of the kidneys. Front Pharmacol. 2023;14:1215996. [PubMed] [DOI] [Cited in This Article: ] [Cited by in F6Publishing: 2] [Reference Citation Analysis (0)] |
| 24. | Tuleta I, Frangogiannis NG. Fibrosis of the diabetic heart: Clinical significance, molecular mechanisms, and therapeutic opportunities. Adv Drug Deliv Rev. 2021;176:113904. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 49] [Cited by in F6Publishing: 56] [Article Influence: 18.7] [Reference Citation Analysis (0)] |
| 25. | Jia G, DeMarco VG, Sowers JR. Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy. Nat Rev Endocrinol. 2016;12:144-153. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 604] [Cited by in F6Publishing: 565] [Article Influence: 70.6] [Reference Citation Analysis (0)] |
| 26. | Lu J, Liu J, Zhang L, Wang X, Zhang Y, Tang Q. Morphological and functional characterization of diabetic cardiomyopathy in db/db mice following exercise, metformin alone, or combination treatments. Biochem Biophys Res Commun. 2021;584:80-86. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis (0)] |
| 27. | Yang F, Qin Y, Wang Y, Meng S, Xian H, Che H, Lv J, Li Y, Yu Y, Bai Y, Wang L. Metformin Inhibits the NLRP3 Inflammasome via AMPK/mTOR-dependent Effects in Diabetic Cardiomyopathy. Int J Biol Sci. 2019;15:1010-1019. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 139] [Cited by in F6Publishing: 261] [Article Influence: 52.2] [Reference Citation Analysis (0)] |
| 28. | Jia W, Bai T, Zeng J, Niu Z, Fan D, Xu X, Luo M, Wang P, Zou Q, Dai X. Combined Administration of Metformin and Atorvastatin Attenuates Diabetic Cardiomyopathy by Inhibiting Inflammation, Apoptosis, and Oxidative Stress in Type 2 Diabetic Mice. Front Cell Dev Biol. 2021;9:634900. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 16] [Cited by in F6Publishing: 35] [Article Influence: 11.7] [Reference Citation Analysis (0)] |
| 29. | Romero SP, Andrey JL, Garcia-Egido A, Escobar MA, Perez V, Corzo R, Garcia-Domiguez GJ, Gomez F. Metformin therapy and prognosis of patients with heart failure and new-onset diabetes mellitus. A propensity-matched study in the community. Int J Cardiol. 2013;166:404-412. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 47] [Cited by in F6Publishing: 50] [Article Influence: 3.8] [Reference Citation Analysis (0)] |
| 30. | Sardu C, Paolisso P, Sacra C, Mauro C, Minicucci F, Portoghese M, Rizzo MR, Barbieri M, Sasso FC, D'Onofrio N, Balestrieri ML, Calabrò P, Paolisso G, Marfella R. Effects of Metformin Therapy on Coronary Endothelial Dysfunction in Patients With Prediabetes With Stable Angina and Nonobstructive Coronary Artery Stenosis: The CODYCE Multicenter Prospective Study. Diabetes Care. 2019;42:1946-1955. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 80] [Cited by in F6Publishing: 101] [Article Influence: 20.2] [Reference Citation Analysis (0)] |
| 31. | Halabi A, Sen J, Huynh Q, Marwick TH. Metformin treatment in heart failure with preserved ejection fraction: a systematic review and meta-regression analysis. Cardiovasc Diabetol. 2020;19:124. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 27] [Cited by in F6Publishing: 41] [Article Influence: 10.3] [Reference Citation Analysis (0)] |
| 32. | Ye H, He Y, Zheng C, Wang F, Yang M, Lin J, Xu R, Zhang D. Type 2 Diabetes Complicated With Heart Failure: Research on Therapeutic Mechanism and Potential Drug Development Based on Insulin Signaling Pathway. Front Pharmacol. 2022;13:816588. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis (0)] |
| 33. | Abdel-Hamid AA, Firgany Ael-D. Atorvastatin alleviates experimental diabetic cardiomyopathy by suppressing apoptosis and oxidative stress. J Mol Histol. 2015;46:337-345. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis (0)] |
| 34. | Al-Rasheed NM, Al-Rasheed NM, Hasan IH, Al-Amin MA, Al-Ajmi HN, Mohamad RA, Mahmoud AM. Simvastatin Ameliorates Diabetic Cardiomyopathy by Attenuating Oxidative Stress and Inflammation in Rats. Oxid Med Cell Longev. 2017;2017:1092015. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 60] [Cited by in F6Publishing: 78] [Article Influence: 11.1] [Reference Citation Analysis (0)] |
| 35. | Greig D, Alcaino H, Castro PF, Garcia L, Verdejo HE, Navarro M, López R, Mellado R, Tapia F, Gabrielli LA, Nogerol C, Chiong M, Godoy I, Lavandero S. Xanthine-oxidase inhibitors and statins in chronic heart failure: effects on vascular and functional parameters. J Heart Lung Transplant. 2011;30:408-413. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis (0)] |
| 36. | Collins R, Armitage J, Parish S, Sleigh P, Peto R; Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361:2005-2016. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 1734] [Cited by in F6Publishing: 1772] [Article Influence: 84.4] [Reference Citation Analysis (0)] |
| 37. | De Geest B, Mishra M. Role of Oxidative Stress in Diabetic Cardiomyopathy. Antioxidants (Basel). 2022;11. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 17] [Cited by in F6Publishing: 49] [Article Influence: 24.5] [Reference Citation Analysis (0)] |
| 38. | El Hayek MS, Ernande L, Benitah JP, Gomez AM, Pereira L. The role of hyperglycaemia in the development of diabetic cardiomyopathy. Arch Cardiovasc Dis. 2021;114:748-760. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 8] [Cited by in F6Publishing: 20] [Article Influence: 6.7] [Reference Citation Analysis (0)] |
| 39. | Philip JL, Razzaque MA, Han M, Li J, Theccanat T, Xu X, Akhter SA. Regulation of mitochondrial oxidative stress by β-arrestins in cultured human cardiac fibroblasts. Dis Model Mech. 2015;8:1579-1589. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 16] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis (0)] |
| 40. | Huang Y, Zhang J, Xu D, Peng Y, Jin Y, Zhang L. SIRT6specific inhibitor OSS128167 exacerbates diabetic cardiomyopathy by aggravating inflammation and oxidative stress. Mol Med Rep. 2021;23. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 3] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis (0)] |
| 41. | Watanabe R, Hilhorst M, Zhang H, Zeisbrich M, Berry GJ, Wallis BB, Harrison DG, Giacomini JC, Goronzy JJ, Weyand CM. Glucose metabolism controls disease-specific signatures of macrophage effector functions. JCI Insight. 2018;3. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 57] [Cited by in F6Publishing: 57] [Article Influence: 9.5] [Reference Citation Analysis (0)] |
| 42. | Mouton AJ, Li X, Hall ME, Hall JE. Obesity, Hypertension, and Cardiac Dysfunction: Novel Roles of Immunometabolism in Macrophage Activation and Inflammation. Circ Res. 2020;126:789-806. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 101] [Cited by in F6Publishing: 247] [Article Influence: 61.8] [Reference Citation Analysis (0)] |
| 43. | Liu G, Yan D, Yang L, Sun Y, Zhan L, Lu L, Jin Z, Zhang C, Long P, Chen J, Yuan Q. The effect of miR-471-3p on macrophage polarization in the development of diabetic cardiomyopathy. Life Sci. 2021;268:118989. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 4] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis (0)] |